However, the supplement with HFLPD inhibited DEGs of CTSE and DMBT1 in mice, suggesting that the probiotic supplement reduced the hepatic inflammation and dyslipidemia via the downregulation of these DEGs. The gene discussed is DMBT1; the disease is metabolic syndrome.